Failure of the Nemo trial: bumetanide is a promising agent to treat many brain disorders but not newborn seizures
The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial; 1). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel therapy for many brain d...
Main Authors: | Yehezkel eBen-Ari, philippe edamier, eric elemonnier |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-04-01
|
Series: | Frontiers in Cellular Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fncel.2016.00090/full |
Similar Items
-
The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis
by: Yehezkel Ben-Ari, et al.
Published: (2022-01-01) -
Longitudinal Effects of Bumetanide on Neuro-Cognitive Functioning in Drug-Resistant Epilepsy
by: Zeinab Gharaylou, et al.
Published: (2019-05-01) -
A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders
by: Eric Delpire, et al.
Published: (2022-08-01) -
Bumetanide for autism spectrum disorder: Current evidence (eng)
by: Mazlum Çöpür, et al.
Published: (2020-11-01) -
Effect of Co-administration of Bumetanide and Phenobarbital on Seizure Attacks in Temporal Lobe Epilepsy
by: Reza Rahmanzadeh, et al.
Published: (2018-11-01)